FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study. (12th February 2014)

• Record Type: Journal Article
• Authors: Balôgôg, P. N.; Tagny, C. T.; Ndoumba, A.; Mbanya, D.
• Is Part Of: International journal of laboratory hematology. Volume 36:Number 5(2014:Oct.)
• Page Start: 566
• Page End: 570
• Publication Date: 2014-02-12
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1111/ijlh.12190
• Languages: English
• ISSNs: 1751-5521

Abstract

<abstract abstract-type="main" id="ijlh12190-abs-0001"> <title>Summary</title> <sec id="ijlh12190-sec-0001" sec-type="section"> <title>Introduction</title> <p>Hemophilia is a reality in Cameroon were more than 100 patients are registered and followed‐up in the Yaoundé Hemophilia treatment center.</p> </sec> <sec id="ijlh12190-sec-0002" sec-type="section"> <title>Aim</title> <p>We conducted a cross sectional study in patient living with hemophilia in that setting in order to determine the frequency of Factor VIII and IX specific inhibitors and the factors associated their presence.</p> </sec> <sec id="ijlh12190-sec-0003" sec-type="section"> <title>Methods</title> <p>From May to December 2012, venous blood samples of hemophiliac patients undergoing replacement therapy were collected in tubes containing 0.109 <sc>m</sc> (3.2%) trisodium citrate. Inhibitors were screened by APTT based method using 50 : 50 patients' plasma mixed with normal plasma incubated together for 2 h at 37 °C. Quantitative assay was carried out to measure Bethesda units (BU) with the Bethesda Nijmegen Assay. Samples were labeled as low titer inhibitor when <5 BU were detected.</p> </sec> <sec id="ijlh12190-sec-0004" sec-type="section"> <title>Results</title> <p>A total of 42 patients were tested among which four had haemophilia B while 38 had hemophilia A. Eight patients (19%) were found to have positive Bethesda test. The mean age of patients with inhibitors was 9.2 ± 6 years (2–18). Two of them were high responders (25%). the frequency of inhibitors was higher in severe hemophiliac patients.</p> </sec> <sec id="ijlh12190-sec-0005" sec-type="section"> <title>Conclusion</title> <p>The frequency of inhibitors in hemophiliac patient undergoing replacement therapy is high in Cameroon. Severity of disease was found to be the main contributing factor in patients who developed inhibitors.</p> </sec> </abstract>